Roche launches newborn screening test for three severe genetic conditions
Roche Diagnostics subsidiary TIB MOLBIOL has launched a new screening test that simultaneously detects Spinal Muscular Atrophy, Severe Combined Immunodeficiency, and Sickle Cell Disease in newborns.
BERLIN – Roche Diagnostics subsidiary TIB MOLBIOL has launched the LightMix® Newborn TREC/SMN1/HBB kit, an in vitro diagnostic test for newborn screening in countries accepting the CE mark. The test simultaneously screens for Spinal Muscular Atrophy (SMA), Severe Combined Immunodeficiency Disease (SCID), and Sickle Cell Disease (SCD).
This new test provides private and academic hospital laboratories with a ready-to-use solution designed to integrate into existing workflows. Early detection of these conditions is critical, allowing clinicians to initiate life-changing treatments before irreversible symptoms or permanent damage manifest, significantly improving patient outcomes.
Spinal Muscular Atrophy (SMA) is a genetic neuromuscular disorder causing progressive muscle weakness. Severe Combined Immunodeficiency (SCID) leaves infants with virtually no immune system, making them highly susceptible to severe infections. Sickle Cell Disease (SCD) is an inherited red blood cell disorder that can lead to blood vessel blockages and serious complications.
The launch aims to equip laboratories with the tools needed for rapid and accurate identification of these potentially life-threatening conditions. By offering a streamlined screening solution, Roche intends to accelerate access to timely interventions and improve the prognosis for affected newborns.